0001628280-26-032557
SEC filingRevenue was $144.8M (96.0%) Gross Profit was $62.0M (-5.8%) Operating Income was -$165.8M (-926.5%) Net Income was -$160.8M (-297.5%)
Gross profit fell 5.8% to $62.0 million, compressing the gross margin to 42.8%. The primary drivers, as noted in management's discussion, were higher rework costs on Automated Stores projects and an increase in excess and obsolete inventory reserves. These operational headwinds overwhelmed any leverage from modestly higher revenue, signaling quality issues in project execution and inventory management that could persist without targeted interventions. The margin contraction underscores the need for cost controls and improved mix to restore profitability pathways.
Operating income deteriorated sharply to -$165.8 million from -$16.2 million, yielding an operating margin of -114.5%. While specific impairment details are not quantified in supported metrics, the swing reflects amplified losses from the identified gross profit drags compounded by operating expense dynamics. Net income followed suit, widening to -$160.8 million or -$3.49 diluted EPS, a 297.5% decline, emphasizing the quarter's profitability challenges.
Management is pursuing portfolio simplification to refocus on core Sample Management Solutions and Multiomics segments, aiming to drive sustainable revenue growth and profitability. Additional restructuring initiatives are under refinement, with impacts to be recognized when criteria are met. Non-cancellable commitments stood at $41.1 million as of period-end, comprising $20.4 million in inventory purchase orders and $20.7 million in other operating expenses, indicating disciplined forward spending amid uncertainty.